360Dx: Quotient Launching Multimodal, Multiplex Microarray for Transfusion Diagnostics

NEW YORK ─ Microarray test developer Quotient has entered the market for transfusion diagnostic testing with a multiplex, multimodal platform and is eyeing the development of the system for additional diagnostic applications. Though sales of the firm’s manually applied Alba by Quotient reagents currently account for almost all of the Eysins, Switzerland-based company’s revenues, Quotient believes its automated microarray platform, MosaiQ, will become a mainstay of its future revenue growth, said Manuel Mendez, who took over as the company’s new CEO at the beginning of April.

To read the full article, visit: 360Dx.com

Trending Topics

Our passion for the work we do is matched only by our commitment to consistently provide the best customer experience possible.